Table 3.
Results presented for each cost category across all three scenarios. Total costs per patient are calculated, and all results are in Euros.
| Clinical practice | Chemotherapy acquisition costs (€) | Chemotherapy administration costs (€) | Short-term AE costs (€) | Long-term AE costs (€) | Productivity losses (€) | GPT test costs (€) | Recurrence costs (€) | Total costs for entire model population (€) | Total costs per patient (€) |
|---|---|---|---|---|---|---|---|---|---|
| Oncotype DX test | €3,343,380 | €4,514,251 | €1,492,789 | €563,146 | €3,321,681 | €9,116,840 | €6,863,702 | €29,215,789 | €14,379 |
| No genomic test | €12,382,889 | €16,719,449 | €5,528,848 | €2,085,726 | €12,302,523 | €0 | €6,863,702 | €55,883,137 | €27,504 |
| MammaPrint | €6,686,760 | €9,028,502 | €2,985,578 | €1,126,292 | €6,643,362 | €7,667,051 | €8,828,722 | €42,966,268 | €21,147 |
| Difference between Oncotype DX test vs. no genomic test | -€9,039,509 | -€12,205,198 | -€4,036,059 | -€1,522,580 | -€8,980,842 | €9,116,840 | €0 | -€26,667,347 | -€13,125 |
| Difference between Oncotype DX test vs. MammaPrint | -€3,343,380 | -€4,514,251 | -€1,492,789 | -€563,146 | -€3,321,681 | €1,449,788 | -€1,965,020 | -€13,750,478 | -€6,768 |
Abbreviations: AE = adverse event; GPT = genomic profile test.